BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

This study is testing a new type of immune cell therapy called CAR-T cells for people with multiple myeloma (a blood cancer) or related plasma cell diseases that have come back or stopped responding to treatment. The therapy uses a patient's own immune cells, re-engineered in a lab to attack cancer cells. **You may be eligible if...** - You have been diagnosed with multiple myeloma or a related plasma cell disease - Your cancer came back or stopped responding to standard chemotherapy - Your cancer relapsed after a stem cell transplant - You are between 18 and 75 years old - Your cancer cells carry the BCMA protein on their surface - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have serious organ problems that would make treatment unsafe - You cannot give informed consent - Your cancer does not have the BCMA marker Talk to your doctor to see if this trial is right for you.